By boosting the expression of SGLT2 in lung premalignancy and early stage lung adenocarcinoma [82], dapagliflozin may be able to inhibit glucose transport and hence reduce the rate at which cancer cells proliferate. This evidence concerns the gene SLC5A2 and cancer.